You are here: Industry Insights > Dravet syndrome

News List

EU green light for Zogenix’s Fintepla pharmatimes
December 24, 2020
The European Commission (EC) has approved Zogenix’s Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome.
Xeris Pharma gets US FDA fast track designation for diazepam non-aqueous injection to treat acute repetitive seizures expresspharma
October 22, 2020
It was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.
FDA Approves New Therapy for Dravet Syndrome americanpharmaceuticalreview
July 07, 2020
The U.S. Food and Drug Administration (FDA) approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older.
US FDA grants approval of Fintepla to Zogenix expresspharma
June 28, 2020
Fintepla offers an additional effective treatment option for the treatment of seizures associated with Dravet syndrome: Zogenix.
Fenfluramine Reduces Convulsive Seizures in Dravet Syndrome drugs
December 19, 2019
Among patients with Dravet syndrome, the reduction in frequency of convulsive seizures is greater with fenfluramine than with placebo, according to a study published online in The Lancet.
Epygenix Submits IND Application for EPX-100 for Dravet Syndrome americanpharmaceuticalreview
June 26, 2019
Epygenix Therapeutics announced the Company has submitted Investigational New Drug Application (IND) and Fast Track Designation Request for EPX-100 to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Dravet syndrome.
US clears new treatment option for Dravet syndrome pharmatimes
August 27, 2018
US regulators have approved Biocodex’ Diacomit for the treatment of seizures associated with Dravet syndrome (DS), a rare and difficult to treat form of epilepsy.
FDA Approves New Treatment for Seizures Associated with Dravet Syndrome americanpharmaceuticalreview
August 24, 2018
The US Food and Drug Administration (FDA) approved Diacomit (stiripentol) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.
Zogenix’ drug cuts seizures in Dravet syndrome pharmatimes
July 16, 2018
The study met its primary endpoint, demonstrating that the drug is superior to placebo as adjunctive therapy to stiripentol in the treatment of children and young adults with the condition, a difficult-to-treat form of childhood-onset epilepsy.
Zogenix’ drug cuts seizures in Dravet syndrome pharmatimes
July 13, 2018
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.